Intracavernous injection of linsidomine chlorhydrate in monkeys: lack of toxic effect with long-term use.
We sought to investigate whether linsidomine chlorhydrate (SIN1, the active metabolite of molsidomine and a nitric oxide donor) has a toxic effect when used chronically for the treatment of impotence. We gave 50 intracavernous injection of 1.5 mg SIN1 over 25 weeks to each of 5 monkeys. Four monkeys consistently responded with erections of sufficient rigidity and duration (mean 47.5 +/- 3.3 min), and none of the five evidenced histopathologic changes of the cavernous tissue. SIN1 appears to be a safe option for the pharmacotherapy of erectile dysfunction.